Hjem › Endometriekreft › California › San Francisco
Kliniske studier for Endometriekreft i San Francisco, CA
14 studier for Endometriekreft søker deltakere på steder i og rundt San Francisco (innen ca. 30 miles). Åpne et studie for å se hvem som kan delta og hvordan du kontakter studieteamet.
Offisiell studietekst (engelsk)
Rekrutterer til et studie her? Få det fremtredende øverst på siden – $99 i 30 dager →
Testing the Addition of an Antiangiogenic Drug (Bevacizumab) to Chemotherapy (Carboplatin and Paclitaxel) Combined With Immunotherapy (Pembrolizumab) for pMMR, TP53 Mutated Endometrial Cancer
RekruttererFase 3
- Kaiser Permanente-San Francisco, San Francisco
Distance-Based Exercise to Preserve Function and Prevent Disability
Rekrutterer
- Kaiser Permanente-San Francisco, San Francisco
Study to Assess the Efficacy and Safety of Rina-S Compared to Treatment of Investigator's Choice in Participants With Endometrial Cancer
RekruttererFase 3
- CPMC Research Institute, San Francisco
Phase 1, Safety and Tolerability Study of XmAb541 in Advanced Solid Tumors
RekruttererFase 1
- University of California, San Francisco
Tegavivint for the Treatment of Recurrent or Refractory Solid Tumors, Including Lymphomas and Desmoid Tumors
RekruttererFase 1/2
- UCSF Medical Center-Mission Bay, San Francisco
FOG-001 in Locally Advanced or Metastatic Solid Tumors
RekruttererFase 1/2
- University of California San Francisco, Helen Diller Family Comprehensive Cancer Center, San Francisco
A Study of DM002 in Patients With Advanced Solid Tumors
RekruttererFase 1/2
- University of California San Francisco Cancer Center, San Francisco
Relacorilant in Combination With Different Treatment Regimens in Patients With Gynecological Cancers
RekruttererFase 2
- 014, San Francisco
First-in-Human Study of Tersolisib (STX-478) as Monotherapy and in Combination With Other Antineoplastic Agents in Participants With Advanced Solid Tumors
RekruttererFase 1/2
- UCSF Medical Center at Mission Bay, San Francisco
A Study of Emiltatug Ledadotin (Emi-Le) in Participants With Solid Tumors
RekruttererFase 1/2
- UCSF Helen Diller Family Comprehensive Cancer Center, San Francisco
Phase 1/2 Study of ETX-636 in Participants With Advanced Solid Tumors
RekruttererFase 1/2
- UCSF Helen Diller Family Comprehensive Cancer Center, San Francisco
Sapanisertib and Serabelisib (PIKTOR) With Paclitaxel and a Substudy With an Insulin-Suppressing Diet in Patients With Advanced/Recurrent Endometrial Cancer
RekruttererFase 2
- University of California, San Francisco (UCSF), San Francisco
Zanzalintinib in Combination With Paclitaxel in Recurrent High Grade Uterine Cancer
RekruttererFase 1
- University of California, San Francisco, San Francisco
SYNERGY-AI: Artificial Intelligence Based Precision Oncology Clinical Trial Matching and Registry
RekruttererObservasjonsstudie
- Massive Bio SYNERGY-AI site, San Francisco
Endometriekreft-studier i andre byer
- Houston, TX68 studier
- New York City, NY52 studier
- Boston, MA50 studier
- Arlington, VA39 studier
- Nashville, TN38 studier
- Los Angeles, CA34 studier
- St. Louis, MO29 studier
- Philadelphia, PA28 studier
- San Antonio, TX27 studier
- Columbus, OH25 studier
- Oklahoma City, OK25 studier
- Chicago, IL25 studier
Andre studier i San Francisco
- Prostatakreft45 studier
- Brystkreft43 studier
- Ikke-småcellet lungekreft36 studier
- Kreft (alle typer)35 studier
- Hjertesvikt29 studier
- Metastatisk kreft28 studier
- Lungekreft22 studier
- Melanom22 studier
- Pankreaskreft20 studier
- Eggstokkreft19 studier
- Kolorektal kreft18 studier
- Kardiovaskulær sykdom18 studier
Fra ClinicalTrials.gov, data hentet 6. okt. 2026. Hver studie setter sine egne kvalifikasjonskrav; studieteamet avgjør hvem som kan delta.